Green Cross Holdings Corporation Stock price

Equities

A005250

KR7005250006

Pharmaceuticals

End-of-day quote Korea S.E. 07:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
17,350 KRW -1.87% Intraday chart for Green Cross Holdings Corporation +1.23% +6.12%
Sales 2022 2,080B 1.54B Sales 2023 2,058B 1.53B Capitalization 746B 553M
Net income 2022 32.82B 24.35M Net income 2023 -54.14B -40.17M EV / Sales 2022 0.79 x
Net Debt 2022 858B 637M Net Debt 2023 1,084B 804M EV / Sales 2023 0.89 x
P/E ratio 2022
23.8 x
P/E ratio 2023
-13.5 x
Employees 165
Yield 2022
1.76%
Yield 2023
-
Free-Float 43.91%
More Fundamentals * Assessed data
Dynamic Chart
Tiantan Biological Unit Registers Blood Disorder Treatment; Shares Jump 4% MT
Green Cross's Net Income Plunges in Q2 MT
South Korea's FTC Imposes 40.9 Billion Won in Fines on Drug Firms for Bid-Rigging MT
Feldan Therapeutics announced that it has received $16.5 million in funding from Amgen Ventures, Investissement Québec, Investment Arm, Green Cross Holdings Corporation and other investors CI
Green Cross Holdings Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Green Cross Swings to Loss in Q1 MT
Feldan Bio Inc. announced that it has received funding from Green Cross Holdings Corporation, Consortium Québécois sur la Découverte du Médicament, Centre for Commercialization of Regenerative Medicine CI
Green Cross' Net Profit Falls 27% in Q3 MT
Green Cross Holdings Corporation completed the acquisition of Highlander Factory, Inc. from New Jersey Innovation Institute Inc. CI
Green Cross' Net Income Rises 3% in March Quarter MT
Green Cross Holdings Corporation signed an agreement to acquire Highlander Factory, Inc. from New Jersey Innovation Institute Inc. for $73 million. CI
MedAdvisor Expands to New Zealand with Green Cross Health Deal MT
Green Cross Lab Cell Corporation completed the acquisition of Green Cross Cell Corporation from a group of shareholders. CI
Green Cross Lab Cell Corporation entered into a definitive merger agreement to acquire Green Cross Cell Corporation from a group of shareholders for approximately KRW 510 billion. CI
Aqua Metals : Start-ups aim to change car battery recycling, clean up world's most polluting industry RE
More news
1 day-1.87%
1 week+1.23%
Current month+5.15%
1 month+1.76%
3 months+9.46%
6 months+24.46%
Current year+6.12%
More quotes
1 week
17 310.00
Extreme 17310
17 990.00
1 month
16 170.00
Extreme 16170
17 990.00
Current year
14 670.00
Extreme 14670
17 990.00
1 year
12 920.00
Extreme 12920
17 990.00
3 years
12 920.00
Extreme 12920
41 550.00
5 years
12 920.00
Extreme 12920
56 300.00
10 years
12 920.00
Extreme 12920
62 000.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 49 10-02-28
Chief Executive Officer 69 91-05-31
Director of Finance/CFO 51 -
Members of the board TitleAgeSince
Chief Executive Officer 69 91-05-31
Director/Board Member 74 09-02-28
Chief Executive Officer 49 10-02-28
More insiders
Date Price Change Volume
24-03-27 17,350 -1.87% 68 514
24-03-27 17,680 -0.67% 74,484
24-03-26 17,800 +0.06% 77,814
24-03-25 17,790 +0.51% 69,944
24-03-22 17,700 +1.32% 108,155

End-of-day quote Korea S.E., March 27, 2024

More quotes
Green Cross Holdings Corp is a Korea-based investment holding company principally engaged in the manufacture and distribution of pharmaceuticals. The Company's products portfolio consists of prescription drugs, blood derivatives, vaccines, cerebrovascular disease treatment, hunter syndrome drugs, as well as over the counter (OTC) drugs, such as skin disease treatment drugs, allergic cream and others. Its products are used for analgesic, treatment of cerebral thrombosis, hypoalbuminemia, genodermatosis and others, as well as prevention of influenza, prophylaxis of varicella, among others. The Company is also involved in the real estate sales and leasing, as well as construction business.
More about the company
  1. Stock
  2. Equities
  3. Stock Green Cross Holdings Corporation - Korea S.E.